Companies / India
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
India's IBPL To Launch Oncology Biotech Products
February 2008 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Demonstrating faith in the Gulf states' appetite for novel drugs, India's Intas Biopharmaceuticals (IBPL) is to register itself in the Gulf Co-operation Council (GCC) region. IBPL is initially planning to launch three products to treat certain cancers and their side effects in the GCC. The products due to be launched are Neukine (rHu G-CSF), Erykine (rHu EPO) and Intalfa (rHu interferon alpha